AbbVie
AbbVie Inc (ABBV) is a large-cap biopharmaceutical company known for established prescription medicines and an expanding pipeline. Historically driven by a few high-revenue products, AbbVie has sought to diversify through R&D, new product launches and acquisitions. The company generates significant free cash flow and is a regular dividend payer, which may attract income-focused investors. Key considerations for potential investors include patent and competition risks (including biosimilars), the outcome of clinical trials, regulatory approvals and pricing pressure in major markets. Market-cap scale and a broad geographic footprint can offer resilience, but revenues can be volatile around patent cliffs and product lifecycle events. This summary is for general educational purposes only and is not personal investment advice; investors should assess their own risk tolerance, time horizon and seek independent advice before acting. Past performance is not a guide to future results.
Why It's Moving
Analysts Rally Behind ABBV with Strong Buy Consensus Pointing to Significant Upside Potential Through 2026
- Over 30 analysts across major firms rate ABBV as a Buy, with zero Sell recommendations and median targets implying 20-35% upside from recent trading around $200-220.
- Recent updates from firms like Piper Sandler highlight targets up to $289, signaling robust expectations for AbbVie's immunology and oncology franchises.
- The strong outperform consensus from 28 analysts underscores AbbVie's resilient earnings trajectory amid a stable pharma environment.
Analysts Rally Behind ABBV with Strong Buy Consensus Pointing to Significant Upside Potential Through 2026
- Over 30 analysts across major firms rate ABBV as a Buy, with zero Sell recommendations and median targets implying 20-35% upside from recent trading around $200-220.
- Recent updates from firms like Piper Sandler highlight targets up to $289, signaling robust expectations for AbbVie's immunology and oncology franchises.
- The strong outperform consensus from 28 analysts underscores AbbVie's resilient earnings trajectory amid a stable pharma environment.
When is the next earnings date for AbbVie (ABBV)?
AbbVie's next earnings date is scheduled for April 29, 2026, before market open, covering the first quarter of 2026 results. This follows their most recent Q4 2025 report released on February 4, 2026. A conference call is anticipated at 9:00 AM ET to discuss the outcomes.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AbbVie stock with a target price of $246.66, indicating good investment potential.
Financial Health
AbbVie is producing strong revenue and profits, supported by impressive cash flow and margins.
Dividend
AbbVie's dividend yield of 3.35% offers a steady income for investors. If you invested $1000 you would be paid $66.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
APELLIS PHARMACEUTICALS INC
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.
AMNEAL PHARMACEUTICALS INC
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
Baskets Featuring ABBV
Beyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketMarket Indecision
Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.
Published: June 18, 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: June 17, 2025
Explore BasketMind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketLow Volatility Stocks
Are you feeling seasick? Sail through calmer waters with these lower volatility investments. These handpicked stocks were carefully selected by our analysts for their history of stability and potential for consistent returns over time.
Published: May 21, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketTop Dividend Paying Stocks
These reliable companies have a proven track record of sharing profits with investors through regular dividend payments. Carefully selected by our professional analysts, these stocks offer the potential for both steady income and long-term growth.
Published: May 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Large-cap pharma value
Generates strong cash flows and has a track record of dividends, which may suit income-oriented allocations — though yields and share performance can fluctuate.
Pipeline and innovation
New drug approvals and successful trials can drive growth, but R&D outcomes are uncertain and clinical setbacks are possible.
Global market exposure
A broad geographic footprint diversifies revenue sources, while differing regulations and pricing environments create both opportunity and risk.
Compare AbbVie with other stocks
AbbVie vs Bristol Myers Squibb
AbbVie vs Bristol Myers Squibb: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
